The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates
- PMID: 17657478
- DOI: 10.1007/s00213-007-0887-8
The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates
Abstract
Rationale: The scopolamine-reversal model is enjoying a resurgence of interest in clinical studies as a reversible pharmacological model for Alzheimer's disease (AD). The cognitive impairment associated with scopolamine is similar to that in AD. The scopolamine model is not simply a cholinergic model, as it can be reversed by drugs that are noncholinergic cognition-enhancing agents.
Objectives: The objective of the study was to determine relevance of computer-assisted operant-conditioning tasks in the scopolamine-reversal model in rats and monkeys.
Materials and methods: Rats were evaluated for their acquisition of a spatial reference memory task in the Morris water maze. A separate cohort was proficient in performance of an automated delayed stimulus discrimination task (DSDT). Rhesus monkeys were proficient in the performance of an automated delayed matching-to-sample task (DMTS).
Results: The AD drug donepezil was evaluated for its ability to reverse the decrements in accuracy induced by scopolamine administration in all three tasks. In the DSDT and DMTS tasks, the effects of donepezil were delay (retention interval)-dependent, affecting primarily short delay trials. Donepezil produced significant but partial reversals of the scopolamine-induced impairment in task accuracies after 2 mg/kg in the water maze, after 1 mg/kg in the DSDT, and after 50 microg/kg in the DMTS task.
Conclusions: The two operant-conditioning tasks (DSDT and DMTS) provided data most in keeping with those reported in clinical studies with these drugs. The model applied to nonhuman primates provides an excellent transitional model for new cognition-enhancing drugs before clinical trials.
Similar articles
-
Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping.Psychopharmacology (Berl). 2006 Nov;188(4):629-40. doi: 10.1007/s00213-006-0556-3. Epub 2006 Sep 27. Psychopharmacology (Berl). 2006. PMID: 17004085
-
Strain-dependent effects on acquisition and reversal of visual and spatial tasks in a rat touchscreen battery of cognition.Physiol Behav. 2015 May 15;144:26-36. doi: 10.1016/j.physbeh.2015.03.001. Epub 2015 Mar 3. Physiol Behav. 2015. PMID: 25744936
-
Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats.Neurobiol Learn Mem. 2011 Sep;96(2):392-402. doi: 10.1016/j.nlm.2011.06.015. Epub 2011 Jul 3. Neurobiol Learn Mem. 2011. PMID: 21757018
-
The Revival of Scopolamine Reversal for the Assessment of Cognition-Enhancing Drugs.In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 17. In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 17. PMID: 21204339 Free Books & Documents. Review.
-
[Pre-clinical evaluation of effects of acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: PET study in conscious monkeys].Nihon Yakurigaku Zasshi. 2004 Sep;124(3):153-61. doi: 10.1254/fpj.124.153. Nihon Yakurigaku Zasshi. 2004. PMID: 15333988 Review. Japanese.
Cited by
-
TAK-071, a muscarinic M1 receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys.PLoS One. 2019 Mar 11;14(3):e0207969. doi: 10.1371/journal.pone.0207969. eCollection 2019. PLoS One. 2019. PMID: 30856192 Free PMC article.
-
The scopolamine model as a pharmacodynamic marker in early drug development.Psychopharmacology (Berl). 2012 Mar;220(1):97-107. doi: 10.1007/s00213-011-2456-4. Epub 2011 Sep 8. Psychopharmacology (Berl). 2012. PMID: 21901320 Clinical Trial.
-
The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice.Alzheimers Res Ther. 2013 May 14;5(3):25. doi: 10.1186/alzrt179. eCollection 2013. Alzheimers Res Ther. 2013. PMID: 23673233 Free PMC article.
-
A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.Biochem Pharmacol. 2009 Oct 1;78(7):852-62. doi: 10.1016/j.bcp.2009.06.102. Epub 2009 Jul 3. Biochem Pharmacol. 2009. PMID: 19577545 Free PMC article.
-
The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys.Br J Pharmacol. 2011 Oct;164(3):970-8. doi: 10.1111/j.1476-5381.2011.01432.x. Br J Pharmacol. 2011. PMID: 21486290 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical